Zydus Lifesciences has achieved a significant milestone by obtaining tentative approval from the US FDA for Dapagliflozin Tablets. Designed...

Indian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...

Glenmark Pharmaceuticals has launched a triple-fixed-dose combination drug called Zita for the treatment of Type 2 diabetes. The drug, whic...

AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatme...

The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients,...

Anglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...

The cost for treating diabetes is expected to come down with the Delhi high court having dismissed an appeal by AstraZeneca, which had soug...

"Sun Pharma has now acquired the rights to trademarks Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of Ast...

AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapaglifl...

The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment...

The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets...

The once-daily tablets are indicated as an adjunct to diet and exercise, and aim to improve glycemic control in adults with Type 2 diabetes...

Glenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin an...

The launch gives Natco an entry in the rapidly growing SGLT-2 segment that has mostly been dominated by global drug makers. However, for ro...

Quoting IQVIA sales data, the company said, Dapagliflozin Tablets, have an estimated market size of USD 1.7 billion for 12 months, ending D...

Diabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide.

The other existing medicines for type-2 diabetes do not work through kidneys and rather use pancreas as a pathway.